Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Diagnostics Faces Nasdaq Delisting

NEW YORK (GenomeWeb) – Interpace Diagnostics' stock faces delisting from the Nasdaq due to the company's failure to maintain a minimum of $2.5 million in stockholders' equity, according to a document filed yesterday with the US Securities and Exchange Commission. 

According to Interpace, it received a written notice from Nasdaq on Nov. 23 indicating its failure to meet the listing requirement. For the three-month period ended Sept. 30, the molecular diagnostics developer reported a total shareholders' deficit of approximately $1.5 million.

Interpace said it was also notified that it did not meet Nasdaq's alternative requirements based on the market value of listed securities or net income from continuing operations. The company has 45 calendar days to provide the exchange with a plan to regain compliance, and may be granted a 180-day extension from the date of the notice to regain compliance.
 
Interpace said that it is considering available options regarding its Nasdaq compliance.
The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.